Vermillion Wealth Management »

Perspective Therapeutics shares owned by Vermillion Wealth Management

Quarter-by-quarter ownership of Perspective Therapeutics (CATX) shares owned by Vermillion Wealth Management from 13F filings

Historical chart of Vermillion Wealth Management investment in Perspective Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Perspective Therapeutics held by Vermillion Wealth Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Perspective Therapeutics by Vermillion Wealth Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $664 194 3.43
2025-06-30 $666 194 3.44
2025-03-31 $413 194 2.13
2024-12-31 $618 194 3.19

More positions owned by Vermillion Wealth Management

Dimensional Etf Trust Us Equity Market (DFUS)
Vanguard Bd Index Fds Total Bnd Mrkt (BND)
Dimensional Etf Trust Core Fixed Incom (DFCF)
Schwab Short-term Bond Index Schwab Mutl Funds (SWSBX)
Dimensional Etf Trust Intl Core Eqt Mk (DFAI)
Vanguard World Inf Tech Etf (VGT)
Dimensional Etf Trust Global Ex Us Cor (DFGX)
Dimensional Etf Trust Us Small Cap Etf (DFAS)
Dfa Us Large Company I Equity Funds (DFUSX)
Schwab Us Treasury Money Investor Schwab Non-sweep Mmf (SNSXX)
Vanguard Specialized Funds Div App Etf (VIG)
Berkshire Hathaway Inc Del Cl B New (BRK.B)
Vanguard Tax-exempt Bond Index Admiral Bond Funds (VTEAX)
Dimensional Etf Trust Emgr Cre Eqt Mng (DFAE)
Schwab S&p 500 Index Schwab Mutl Funds (SWPPX)

View all positions for Vermillion Wealth Management

Top funds holding Perspective Therapeutics

FMR
BlackRock
Vanguard Group
Avidity Partners Management
Millennium Management
Morgan Stanley
Nicholson Wealth Management Group
Geode Capital Management
Nuveen
State Street Corporation
Hills Bank And Trust Company
UBS Group
Walleye Trading Advisors
Charles Schwab Investment Management
Two Sigma Investments

View all funds holding Perspective Therapeutics